THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC: Form 990, tax year 2022
View the entire original 990 at ProPublica ↗
- Organization
- THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC (EIN 06-1504413)
- Tax period
- 2022-01-01 to 2022-12-31
- Filed
- 2023-10-30
- IRS object ID
- 202313039349302071
- Schema version
- 2022v5.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2023-10-30T15:36:30-05:00 | ReturnTs |
| Tax Period End | 2022-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 873231666 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | PKF O'CONNOR DAVIES ADVISORY LLC | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3001 SUMMER STREET 5TH FLOOR EAST | AddressLine1Txt |
| City | STAMFORD | CityNm |
| State Abbreviation | CT | StateAbbreviationCd |
| ZIP | 06905 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2022-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 061504413 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE MULTIPLE MYELOMA RESEARCH | BusinessNameLine1Txt |
| Business Name Line2 | FOUNDATION INC | BusinessNameLine2Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | MULT | BusinessNameControlTxt |
| Phone | 2032290464 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 383 MAIN AVE 5TH FL | AddressLine1Txt |
| City | NORWALK | CityNm |
| State Abbreviation | CT | StateAbbreviationCd |
| ZIP | 06851 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | ROBERT MIANI | PersonNm |
| Person Title | TREASURER/CFO | PersonTitleTxt |
| Phone | 2032290464 | PhoneNum |
| Signature | 2023-10-30 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Signing Officer SigningOfficerGrp
Person Full Name PersonFullName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person First | ROBERT | PersonFirstNm |
| Person Last | MIANI | PersonLastNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| SSN | XXX-XX-XXXX | SSN |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IRS Responsible Prty Info Curr | Yes (1) | IRSResponsiblePrtyInfoCurrInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | GARRETT M HIGGINS | PreparerPersonNm |
| PTIN | P00543209 | PTIN |
| Phone | 2033232400 | PhoneNum |
| Preparation | 2023-10-30 | PreparationDt |
Additional Filer Information AdditionalFilerInformation
Trusted Customer TrustedCustomerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Trusted Customer | 3 | TrustedCustomerCd |
| Authentication Assurance Level | AAL1 | AuthenticationAssuranceLevelCd |
| Identity Assurance Level | IAL1 | IdentityAssuranceLevelCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2022 | TaxYr |
| Build TS | 2023-04-26 12:10:37Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | MICHAEL ANDREINI | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 383 MAIN AVE 5TH FL | AddressLine1Txt |
| City | NORWALK | CityNm |
| State Abbreviation | CT | StateAbbreviationCd |
| ZIP | 06851 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $138,076,621 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.THEMMRF.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1998 | FormationYr |
| Legal Domicile State | CT | LegalDomicileStateCd |
| Activity Or Mission | SEE SCHEDULE O | ActivityOrMissionDesc |
| Voting Members Governing Body | 17 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 16 | VotingMembersIndependentCnt |
| Total Employee | 80 | TotalEmployeeCnt |
| Total Volunteers | 459 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $37,089,868 | PYContributionsGrantsAmt |
| CY Contributions Grants | $42,022,114 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $2,348,850 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $2,152,800 | CYProgramServiceRevenueAmt |
| PY Investment Income | $2,872,478 | PYInvestmentIncomeAmt |
| CY Investment Income | $670,999 | CYInvestmentIncomeAmt |
| PY Other Revenue | $0 | PYOtherRevenueAmt |
| CY Other Revenue | $198,561 | CYOtherRevenueAmt |
| PY Total Revenue | $42,311,196 | PYTotalRevenueAmt |
| CY Total Revenue | $45,044,474 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $6,629,658 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $4,589,741 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $11,130,870 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $10,374,937 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $4,898,025 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $19,886,535 | PYOtherExpensesAmt |
| CY Other Expenses | $23,316,052 | CYOtherExpensesAmt |
| PY Total Expenses | $37,647,063 | PYTotalExpensesAmt |
| CY Total Expenses | $38,280,730 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $4,664,133 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $6,763,744 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $85,401,847 | TotalAssetsBOYAmt |
| Total Assets EOY | $89,097,661 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $28,167,047 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $25,407,747 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $57,234,800 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $63,689,914 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | SEE SCHEDULE O | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $7,028,145 | ExpenseAmt |
| Grant | $1,363,694 | GrantAmt |
| Revenue | $2,345,361 | RevenueAmt |
| Desc | THE IMMUNE SYSTEM IS A CRITICAL FACTOR IN MYELOMA PROGNOSIS AND TREATMENT BECAUSE IT CAN DETECT AND DESTROY ABNORMAL CELLS, INCLUDING CANCER CELLS. TO ADVANCE OUR UNDERSTANDING OF HOW A MYELOMA PATIENT'S IMMUNE SYSTEM CHANGES DURING THE DEVELOPMENT OF THEIR DISEASE AND HOW IT IS AFFECTED BY THERAPY, WE ARE DEVELOPING AN IMMUNE FOCUSED DATABASE, CALLED THE MMRF IMMUNE ATLAS. IT UTILIZES PATIENT SAMPLES AND CLINICAL DATA FROM OUR GROUNDBREAKING COMMPASS STUDY - ONE OF THE LARGEST MYELOMA DATASETS IN THE PUBLIC DOMAIN. THE IMMUNE ATLAS IS DESIGNED TO DESCRIBE THE MYELOMA PATIENT IMMUNE SYSTEM FROM DISEASE DEVELOPMENT, THROUGH DIAGNOSIS, AND THE TREATMENT JOURNEY. THE INFORMATION, COLLECTED FROM HUNDREDS OF PATIENTS, WILL BE COMBINED WITH THE EXISTING GENOMIC AND CLINICAL DATA FROM COMMPASS TO DEVELOP A MORE COMPREHENSIVE PICTURE OF MYELOMA DISEASE BIOLOGY. THE INSIGHTS GENERATED THROUGH IMMUNE ATLAS WILL HELP GUIDE OPTIMAL TREATMENT APPROACHES FOR MYELOMA PATIENTS IN THE FUTURE. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $3,226,047 | ExpenseAmt |
| Grant | $3,226,047 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | THE MMRF CURECLOUD IS A FIRST-OF-ITS-KIND REGISTRY THAT COLLECTS GENOMIC AND CLINICAL INFORMATION TO INFORM BETTER TREATMENTS FOR PATIENTS. THE AGGREGATED DATA IS ALSO DESIGNED TO HELP RESEARCHERS DISCOVER NEW TARGETS FOR MYELOMA AND FORM HYPOTHESES FOR CLINICAL TRIALS.PATIENTS PARTICIPATING IN CURECLOUD CONTRIBUTE A BLOOD SAMPLE THAT IS SENT TO A CENTRAL LAB FOR DNA SEQUENCING. THIS SEQUENCING DATA IS COMBINED WITH THE PATIENT'S MEDICAL RECORDS TO PROVIDE A BETTER UNDERSTANDING OF THEIR DISEASE HISTORY. ALL PATIENT DATA STORED IN CURECLOUD IS THEN ANONYMIZED, AGGREGATED, AND WILL BE SHARED WITH RESEARCHERS AND MEDICAL PROFESSIONALS. TO DATE, MORE THAN 1,000 PATIENTS HAVE ENROLLED. IN THE FALL OF 2022, TWO PATIENT REPORTED OUTCOME (PRO) SURVEYS WERE ADMINISTERED TO CURECLOUD PARTICIPANTS IN ORDER TO TRACK PATIENT EXPERIENCES WITH MYELOMA THERAPY OVER TIME AND ACROSS TREATMENTS. THE CANCER THERAPY SATISFACTION QUESTIONNAIRE MEASURED EXPECTATIONS OF THERAPY, FEELINGS ABOUT SIDE EFFECTS, AND SATISFACTION WITH CANCER THERAPY. THE FACIT COST SURVEY MEASURED THE FINANCIAL IMPACT RELATED TO THERAPY EXPERIENCED BY MYELOMA PATIENTS. CURECLOUD WILL BE CLOSING PATIENT ENROLLMENT AT THE END OF 2023. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $2,713,588 | ExpenseAmt |
| Grant | $0 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | THE MULTIPLE MYELOMA RESEARCH CONSORTIUM (MMRC) IS A NETWORK OF LEADING MYELOMA TREATMENT CENTERS THAT CONDUCT EARLY-STAGE CLINICAL TRIALS TO EVALUATE NOVEL TREATMENT STRATEGIES FOR PATIENTS. THIS COLLABORATIVE RESEARCH MODEL HAS CONDUCTED CLOSE TO 100 PHASE I AND PHASE II CLINICAL TRIALS, ENROLLING OVER A THOUSAND PATIENTS TO DATE. THE MMRC CONTINUES TO SUCCESSFULLY FOSTER THE DEVELOPMENT OF NOVEL THERAPIES AND CHAMPION RIGOROUS RESEARCH AND CLINICAL TRIALS. CURRENT MMRC CLINICAL TRIALS THAT HAVE THE POTENTIAL TO MAKE SIGNIFICANT CONTRIBUTIONS FOR MYELOMA TREATMENT INCLUDE: MYDRUGTHE MMRF MYDRUG STUDY IS THE FIRST PLATFORM TRIAL IN MYELOMA. THE PURPOSE OF MYDRUG IS TO TEST TARGETED THERAPIES NOT YET APPROVED IN MYELOMA, IN COMBINATION WITH A STANDARD OF CARE ORAL TRIPLET THERAPY, IN FUNCTIONALLY HIGH-RISK MULTIPLE MYELOMA PATIENTS WHO DEMONSTRATE SPECIFIC GENETIC ALTERATIONS. IT IS EVALUATING TREATMENTS THAT ARE TARGETED AGAINST SPECIFIC GENOMIC ALTERATIONS WITHIN THE MYELOMA CELLS.THE SCIENTIFIC HYPOTHESIS FOR THE MYDRUG CLINICAL TRIAL CAME OUT OF OUR COMMPASS STUDY, WHICH HAS GENERATED THE LARGEST MYELOMA GENOMICS DATABASE OPENLY ACCESSIBLE TO RESEARCHERS ACROSS THE GLOBE. THE MYDRUG STUDY IS EXPECTED TO CLOSE NEW ENROLLMENTS IN 2024. ELO-IBER (RELAPSED/REFRACTORY)IBERDOMIDE (CC-220) IS A NEW AND POTENTIALLY MORE POTENT MEMBER OF A CLASS OF MEDICINES KNOWN AS IMMUNOMODULATORS (IMIDS), WHICH INCLUDES REVLIMID (LENALIDOMIDE) AND POMALYST (POMALIDOMIDE). THIS IS A PHASE 1B/2 STUDY THAT WILL HELP DETERMINE THE OPTIMAL DOSE OF IBERDOMIDE THAT CAN BE GIVEN TO PATIENTS - IN COMBINATION WITH EMPLICITI (ELOTUZUMAB) AND DEXAMETHASONE - THAT IS SAFE AND HAS THE FEWEST SIDE EFFECTS. ARCELLX (RELAPSED/REFRACTORY)CART-DDBCMA IS A CAR-T CELL THERAPY CANDIDATE THAT USES PATIENT T CELLS THAT HAVE BEEN GENETICALLY MODIFIED TO RECOGNIZE AND KILL MYELOMA CELLS. THIS NEWER VERSION OF CAR-T CELL THERAPY IS DESIGNED TO FORM A STRONGER BOND TO BCMA, A COMMON TARGET FOR MYELOMA TREATMENT, AND KILL MYELOMA CELLS MORE EFFICIENTLY THAN PREVIOUS THERAPIES. BEIGENE (RELAPSED/REFRACTORY)THIS PHASE I/II STUDY IS EVALUATING HOW SAFE AND EFFECTIVE A NEW TARGETED THERAPY (BGB-11417) IS ALONE, AND IN COMBINATION WITH KYPROLIS (CARFILZOMIB) AND DEXAMETHASONE, IN PEOPLE WITH RELAPSED OR REFRACTORY MYELOMA. BGB-11417 IS A BCL-2 INHIBITOR THAT IS POTENTIALLY EFFECTIVE IN MYELOMA PATIENTS WITH THE 11;14 CHROMOSOMAL TRANSLOCATION, WHICH ACCOUNTS FOR ABOUT 20% OF PATIENTS. SARCAR IST THIS TRIAL WILL DETERMINE THE SIDE EFFECTS AND BEST DOSE OF SARCLISA (ISATUXIMAB) WHEN GIVEN TOGETHER WITH CARFILZOMIB WITH OR WITHOUT DEXAMETHASONE AND LENALIDOMIDE IN TREATING PATIENTS WITH RELAPSED/REFRACTORY MYELOMA. IN ARM 1, IT WILL DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF SARCLISA IN COMBINATION WITH STANDARD KYPROLIS. IN ARM 2, IT WILL STUDY THE SAFETY AND EFFICACY OF ADDING SARCLISA DOSES EVERY OTHER WEEK IN COMBINATION WITH WEEKLY KYPROLIS AND DEXAMETHASONE. AFTER COMPLETION OF STUDY TREATMENT, PATIENTS ARE FOLLOWED UP AT 30 AND 60 DAYS AND THEN EVERY 3 MONTHS FOR UP TO 3 YEARS. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $19,263,463 | ExpenseAmt |
| Grant | $0 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | IN ADDITION TO THE PROGRAM EXPENSES DESCRIBED ABOVE, CORRESPONDING ACTIVITIES IN ALIGNMENT WITH THE OVERALL GOALS OF THE ORGANIZATION ARE ALSO SUPPORTED. THESE INCLUDE A PORTFOLIO OF CUTTING-EDGE RESEARCH PROGRAMS IN BASIC SCIENCE, WHICH IDENTIFIES NEW TARGETS THROUGH GENOMICS AND PROTEOMICS RESEARCH; VALIDATION STUDIES, WHICH IDENTIFY NEW COMPOUNDS AND COMBINATIONS IN RESEARCH MODELS BASED ON HIGH-PRIORITY TARGETS; AND INNOVATIVE CLINICAL TRIALS OF NOVEL AND COMBINATION TREATMENTS. AS A PATIENT-FOUNDED ORGANIZATION, THE MMRF STANDS TOGETHER WITH THOSE WHO ARE BATTLING MULTIPLE MYELOMA - PATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF STANDS APART WITH ITS INNOVATIVE APPROACH. THE MMRF GENERATES, INTERPRETS, AND ACTIVATES THE LARGEST COLLECTION OF HIGH-QUALITY DATA AND PLACES IT IN THE PUBLIC DOMAIN. THE MMRF ORCHESTRATES THE PEOPLE, PROGRAMS, AND TECHNOLOGIES NECESSARY TO SPEED THE DISCOVERY OF A CURE FOR EACH AND EVERY PATIENT. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $19,263,463 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $0 | TotalOtherProgSrvcGrantAmt |
| Total Other Prog Srvc Revenue | $0 | TotalOtherProgSrvcRevenueAmt |
| Total Program Service Expenses | $32,231,243 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | 0 | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | 0 | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | Yes (1) | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | Yes (1) | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 57 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Employee | 80 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 17 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 16 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | Yes (1) | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Other Website | Yes (X) | OtherWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ROBERT MIANI | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 2036520207 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 383 MAIN AVE 5TH FLOOR | AddressLine1Txt |
| City | NORWALK | CityNm |
| State Abbreviation | CT | StateAbbreviationCd |
| ZIP | 06851 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part VII | Yes (X) | InfoInScheduleOPartVIIInd |
Form990 Part VII Section A Form990PartVIISectionAGrp (32 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| KATHY GIUSTI | ||||||||
| FOUNDER & DIRECTOR | 30.00 | Yes (X) | $736,667 | $0 | $200 | |||
| THOMAS CONHEENEY | ||||||||
| CHAIRMAN | 2.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | ||
| GERALD MCDOUGALL | ||||||||
| VICE CHAIRMAN | 2.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | ||
| KENNETH ANDERSON MD | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| KAREN ANDREWS | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| RODNEY GILMORE | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| DAVID LUCCHINO | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| LORI TAUBER-MARCUS | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| HUGH MARTIN | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| SUSAN MARVIN | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| WILLIAM MCKIERNAN | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| MICHAEL MORTIMER | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| DAVID PARKINSON MD | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| MARIE PINIZZOTTO MD | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| ADRIAN ROSENKRANZ | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| STEVE SHAK MD | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| KIMBERLY WHITE | ||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| MICHAEL ANDREINI | ||||||||
| PRESIDENT & CEO | 40.00 | $494,070 | $0 | $23,408 | Yes (X) | |||
| ROBERT MIANI | ||||||||
| TREASURER & CFO | 40.00 | $359,867 | $0 | $24,796 | Yes (X) | |||
| KAREN DIETZ | ||||||||
| SECRETARY CAO & GENERAL COUNSEL | 40.00 | $271,181 | $0 | $22,980 | Yes (X) | |||
| ANNE QUINN YOUNG | ||||||||
| CHIEF MISSION OFFICER | 40.00 | $341,011 | $0 | $18,849 | Yes (X) | |||
| PETER KOSA | ||||||||
| MIF MANAGING DIRECTOR | 40.00 | $429,658 | $0 | $33,597 | Yes (X) | |||
| GEORGE MULLIGAN | ||||||||
| CHIEF SCIENTIFIC OFFICER | 40.00 | $233,560 | $0 | $25,816 | Yes (X) | |||
| MINDY FLINN | ||||||||
| VP OF DEVELOPMENT | 40.00 | $227,153 | $0 | $27,593 | Yes (X) | |||
| CHRISTOPHER WILLIAMS | ||||||||
| VP OF ALLIANCE MANAGEMENT | 40.00 | $229,055 | $0 | $28,898 | Yes (X) | |||
| HEARN CHO | ||||||||
| CHIEF MEDICAL OFFICER | 32.00 | $208,833 | $0 | $8,353 | Yes (X) | |||
| EVA M LEPISTO | ||||||||
| VP OF INFORMATICS | 40.00 | $204,912 | $0 | $10,606 | Yes (X) | |||
| GREG RUBENSTEIN | ||||||||
| VP OF MARKETING | 40.00 | $212,086 | $0 | $29,910 | Yes (X) | |||
| CHARLES VOLPE | ||||||||
| DIRECTOR, PR & COMMUNCIATIONS | 40.00 | $173,921 | $0 | $22,134 | Yes (X) | |||
| TODD BROOKS | ||||||||
| SR DIRECTOR, DEVELOPMENT | 40.00 | $179,543 | $0 | $7,996 | Yes (X) | |||
| HEATHER STEIGER | ||||||||
| DIRECTOR, DIGITAL MARKETING | 40.00 | $169,691 | $0 | $16,330 | Yes (X) | |||
| JOANNE PUGLIA | ||||||||
| SR DIRECTOR FINANCE, CONTROLLER | 40.00 | $185,860 | $0 | $10,136 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $4,657,068 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $311,602 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 38 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| REDMEDED LLC | |||||
| 5 GREAT VALLEY PARKWAY SUITE 221 | MALVERN | PA | 19355 | CONTINUING MEDICAL EDUCATION | $2,556,819 |
| SEVEN BRIDGES GENOMICS INC | |||||
| 529 MAIN STREET SUITE 6610 | CHARLESTOWN | MA | 02129 | CONTRACT RESEARCH | $1,921,600 |
| TGEN | |||||
| 445 N FIFTH STREET | PHOENIX | AZ | 85004 | CONTRACT RESEARCH | $1,113,529 |
| EVENT 360 INC | |||||
| 55 E JACKSON BLVD SUITE 1030 | CHICAGO | IL | 60604 | EVENT MANAGEMENT | $1,013,482 |
| PROMETHEUS RESEARCH LLC | |||||
| 1 AUDUBON STREET | NEW HAVEN | CT | 06511 | CONTRACT RESEARCH | $1,004,850 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 58 | CntrctRcvdGreaterThan100KCnt |
| All Other Contributions | $42,022,114 | AllOtherContributionsAmt |
| Noncash Contributions | $191,034 | NoncashContributionsAmt |
| Total Contributions | $42,022,114 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | RESEARCH & CLINICAL TRIALS | Desc |
| Business | 541610 | BusinessCd |
| Total Revenue Column | $2,152,800 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $2,152,800 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $2,152,800 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $679,638 | TotalRevenueColumnAmt |
| Exclusion | $679,638 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $192,561 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $192,561 | RelatedOrExemptFuncIncomeAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $93,023,508 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $93,032,147 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | -$8,639 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$8,639 | TotalRevenueColumnAmt |
| Exclusion | -$8,639 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | OTHER INCOME | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $6,000 | TotalRevenueColumnAmt |
| Exclusion | $6,000 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $6,000 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $45,044,474 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $2,345,361 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $676,999 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,532,241 | TotalAmt |
| Program Services | $4,532,241 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $57,500 | TotalAmt |
| Program Services | $57,500 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,961,065 | TotalAmt |
| Program Services | $2,799,433 | ProgramServicesAmt |
| Management And General | $372,096 | ManagementAndGeneralAmt |
| Fundraising | $789,536 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,211,096 | TotalAmt |
| Program Services | $3,682,879 | ProgramServicesAmt |
| Management And General | $489,521 | ManagementAndGeneralAmt |
| Fundraising | $1,038,696 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $170,487 | TotalAmt |
| Program Services | $120,490 | ProgramServicesAmt |
| Management And General | $16,015 | ManagementAndGeneralAmt |
| Fundraising | $33,982 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $404,960 | TotalAmt |
| Program Services | $286,201 | ProgramServicesAmt |
| Management And General | $38,041 | ManagementAndGeneralAmt |
| Fundraising | $80,718 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $627,329 | TotalAmt |
| Program Services | $443,357 | ProgramServicesAmt |
| Management And General | $58,930 | ManagementAndGeneralAmt |
| Fundraising | $125,042 | FundraisingAmt |
Fees For Services Management FeesForServicesManagementGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,050,024 | TotalAmt |
| Program Services | $933,603 | ProgramServicesAmt |
| Management And General | $20,547 | ManagementAndGeneralAmt |
| Fundraising | $95,874 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $116,025 | TotalAmt |
| Program Services | $101,769 | ProgramServicesAmt |
| Management And General | $3,662 | ManagementAndGeneralAmt |
| Fundraising | $10,594 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $60,200 | TotalAmt |
| Program Services | $52,803 | ProgramServicesAmt |
| Management And General | $1,900 | ManagementAndGeneralAmt |
| Fundraising | $5,497 | FundraisingAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,270,865 | TotalAmt |
| Program Services | $7,192,987 | ProgramServicesAmt |
| Management And General | $34,487 | ManagementAndGeneralAmt |
| Fundraising | $1,043,391 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $845,594 | TotalAmt |
| Program Services | $546,766 | ProgramServicesAmt |
| Management And General | $26,688 | ManagementAndGeneralAmt |
| Fundraising | $272,140 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,475,787 | TotalAmt |
| Program Services | $1,331,614 | ProgramServicesAmt |
| Management And General | $4,201 | ManagementAndGeneralAmt |
| Fundraising | $139,972 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,404,775 | TotalAmt |
| Program Services | $1,232,174 | ProgramServicesAmt |
| Management And General | $44,336 | ManagementAndGeneralAmt |
| Fundraising | $128,265 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $227,995 | TotalAmt |
| Program Services | $199,982 | ProgramServicesAmt |
| Management And General | $7,196 | ManagementAndGeneralAmt |
| Fundraising | $20,817 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $647,770 | TotalAmt |
| Program Services | $421,737 | ProgramServicesAmt |
| Management And General | $4,580 | ManagementAndGeneralAmt |
| Fundraising | $221,453 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $886,269 | TotalAmt |
| Program Services | $36,263 | ProgramServicesAmt |
| Fundraising | $850,006 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $951,835 | TotalAmt |
| Program Services | $900,195 | ProgramServicesAmt |
| Management And General | $24,211 | ManagementAndGeneralAmt |
| Fundraising | $27,429 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $160,043 | TotalAmt |
| Program Services | $140,379 | ProgramServicesAmt |
| Management And General | $5,051 | ManagementAndGeneralAmt |
| Fundraising | $14,613 | FundraisingAmt |
Other Expenses OtherExpensesGrp (2 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt |
|---|---|---|
| CLINICAL TRIALS | $6,644,828 | $6,644,828 |
| TISSUE BANKING | $574,042 | $574,042 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $38,280,730 | TotalAmt |
| Program Services | $32,231,243 | ProgramServicesAmt |
| Management And General | $1,151,462 | ManagementAndGeneralAmt |
| Fundraising | $4,898,025 | FundraisingAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Joint Costs | Yes (X) | JointCostsInd |
Total Joint Costs TotalJointCostsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $192,371 | TotalAmt |
| Program Services | $95,308 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $97,063 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $13,953,290 | BOYAmt |
| EOY | $5,060,628 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $21,392,706 | BOYAmt |
| EOY | $13,092,430 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,289,425 | BOYAmt |
| EOY | $5,229,372 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,335,350 | BOYAmt |
| EOY | $8,274,610 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $225,493 | BOYAmt |
| EOY | $896,043 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $6,732,447 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $3,768,321 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,816,801 | BOYAmt |
| EOY | $2,964,126 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $29,648,577 | BOYAmt |
| EOY | $41,091,535 | EOYAmt |
Investments Program Related InvestmentsProgramRelatedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,648,228 | BOYAmt |
| EOY | $11,719,698 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $91,977 | BOYAmt |
| EOY | $769,219 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $85,401,847 | BOYAmt |
| EOY | $89,097,661 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,252,194 | BOYAmt |
| EOY | $15,173,286 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,265,756 | BOYAmt |
| EOY | $43,261 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,157,093 | BOYAmt |
| EOY | $9,131,077 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $492,004 | BOYAmt |
| EOY | $1,060,123 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $28,167,047 | BOYAmt |
| EOY | $25,407,747 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $45,234,580 | BOYAmt |
| EOY | $56,121,149 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,000,220 | BOYAmt |
| EOY | $7,568,765 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $57,234,800 | BOYAmt |
| EOY | $63,689,914 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $85,401,847 | BOYAmt |
| EOY | $89,097,661 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | $6,763,744 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$538,880 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $230,250 | OtherChangesInNetAssetsAmt |
| Info In Schedule O Part XII | Yes (X) | InfoInScheduleOPartXIIInd |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $41,335,585 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $39,651,088 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $25,012,712 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $37,089,868 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $42,022,114 | CurrentTaxYearAmt |
| Total | $185,111,367 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $41,335,585 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $39,651,088 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $25,012,712 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $37,089,868 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $42,022,114 | CurrentTaxYearAmt |
| Total | $185,111,367 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $25,917,183 | SubstantialContributorsTotAmt |
| Public Support Total170 | $159,194,184 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,090,003 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,349,522 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $426,629 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $100,955 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $679,638 | CurrentTaxYearAmt |
| Total | $3,646,747 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year | $6,000 | CurrentTaxYearAmt |
| Total | $6,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $188,764,114 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $16,656,451 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.84330 | PublicSupportCY170Pct |
| Public Support PY170 | 0.81880 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: | FormAndLineReferenceDesc |
| Explanation | OTHER INCOME - 2022 AMOUNT: $ 6,000. | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule D IRS990ScheduleD
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $635,825 | OtherCostOrOtherBasisAmt |
| Depreciation | $314,061 | DepreciationAmt |
| Book Value | $321,764 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $387,762 | OtherCostOrOtherBasisAmt |
| Depreciation | $197,403 | DepreciationAmt |
| Book Value | $190,359 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $5,708,860 | OtherCostOrOtherBasisAmt |
| Depreciation | $3,256,857 | DepreciationAmt |
| Book Value | $2,452,003 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $2,964,126 | TotalBookValueLandBuildingsAmt |
Invst Program Related Org InvstProgramRelatedOrgGrp (9 entries)
| DescDesc | Book ValueBookValueAmt | Method ValuationMethodValuationCd |
|---|---|---|
| CULLINAN MICA CORP. | $1,178,415 | F |
| ABCURO, INC. | $1,393,212 | F |
| INDAPTA THERAPEUTICS | $1,638,075 | F |
| FORTIS THERAPEUTIC | $500,000 | F |
| CYTOIMMUNE THERAPEUTICS | $1,999,995 | F |
| TRIUMVIRA IMMUNOLOGICS | $1,000,001 | F |
| TELO THERAPEUTICS | $1,010,000 | F |
| LUMINARY THERAPEUTICS | $1,000,000 | F |
| KAHR MEDICAL LTD. | $2,000,000 | F |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Program Rltd | $11,719,698 | TotalBookValueProgramRltdAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | OPERATING LEASE LIABILITY | Desc |
| Amt | $1,060,123 | Amt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $1,060,123 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $43,794,577 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | -$538,880 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $855,829 | DonatedServicesAndUseFcltsAmt |
| Revenue Not Reported | $316,949 | RevenueNotReportedAmt |
| Revenue Subtotal | $43,477,628 | RevenueSubtotalAmt |
| Other Revenues Not Included | $1,566,846 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $1,566,846 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $45,044,474 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $37,339,463 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $855,829 | DonatedServicesUseFcltsAmt |
| Expenses Not Reported | $855,829 | ExpensesNotReportedAmt |
| Expenses Subtotal | $36,483,634 | ExpensesSubtotalAmt |
| Other Expenses Not Included | $1,797,096 | OtherExpensesNotIncludedAmt |
| Expenses Not Rpt Fincl Stmt | $1,797,096 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $38,280,730 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART X, LINE 2: | THE MMRF RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE MMRF HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. |
| PART XI, LINE 4B - OTHER ADJUSTMENTS: | SPECIAL EVENT EXPENSES RECLASSED TO PART IX 1,566,846. |
| PART XII, LINE 4B - OTHER ADJUSTMENTS: | SPECIAL EVENT EXPENSES RECLASSED TO PART IX 1,566,846. GRANT REFUND RECLASSED TO PART XI 230,250. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) | 0 | 0 | GRANTMAKING | $30,000 |
| NORTH AMERICA | 0 | 0 | GRANTMAKING | $27,500 |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | INVESTMENTS | $2,000,000 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $2,057,500 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $2,057,500 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (2 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Non Cash AssistanceNonCashAssistanceAmt |
|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) | FELLOW | $30,000 | WIRE | $0 |
| NORTH AMERICA | FELLOW | $27,500 | WIRE | $0 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 2 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (1) | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | Yes (1) | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | MMRF RECEIVES PROGRESS REPORTS ON HOW THE GRANTED FUNDS ARE USED. MMRF CONDUCTS A REVIEW PROCESS, DURING WHICH THE INVESTIGATOR'S PROGRESS REPORT IS REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS APPROPRIATE PROGRESS WAS MADE AND THE FINDINGS SUPPORT CONTINUES STUDY, HE/SHE PRESENTS THE PROGRESS AND FINDINGS TO AN APPROVAL COMMITTEE FOR A FUNDING RELEASE. |
| PART III ACCOUNTING METHOD: | |
| SCHEDULE F, PART IV, LINE 1: | THE ORGANIZATION IS REQUIRED TO FILE FORM 926 AS IT MEETS THE APPLICABLE FILING REQUIREMENT THRESHOLDS. |
| SCHEDULE F, PART IV, LINE 3: | THE ORGANIZATION IS NOT REQUIRED TO FILE FORM 5471 AS DOES NOT MEET THE APPLICABLE FILING REQUIREMENT THRESHOLDS OR OWNERSHIP AMOUNT. |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (19 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|---|
| BARBARA ANN KARMANOS CANCER HOSPITAL | |||||||||
| 4100 JOHN R STREET | DETROIT | MI | 48201 | 201649466 | 501(C)(3) | $30,000 | $0 | SITE INVESTMENT GRANT | |
| BETH ISRAEL DEACONESS MEDICAL CENTER | |||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042103881 | 501(C)(3) | $632,000 | $0 | SITE INVESTMENT GRANT, IMMUNOTHERAPY | |
| CITY OF HOPE | |||||||||
| 1500 EAST DUARTE ROAD MEDICAL | DURATE | CA | 91010 | 953435919 | 501(C)(3) | $27,500 | $0 | SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY | OFFICE BLD 3RD FLOOR |
| DANA FARBER CANCER INSTITUTE | |||||||||
| 44 BINEY ST | BOSTON | MA | 02115 | 042263040 | 501(C)(3) | $2,804,526 | $0 | SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION | |
| EMORY UNIVERSITY | |||||||||
| 1365 CLIFTON RD BLDG C | ATLANTA | GA | 30322 | 580566256 | 501(C)(3) | $110,700 | $0 | SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY, PREVENTION | |
| H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE | |||||||||
| 12902 MAGNOLIA DRIVE | TAMPA | FL | 33612 | 593238634 | 501(C)(3) | $30,000 | $0 | FELLOW | |
| HACKENSACK UNIVERSITY MEDICAL CENTER | |||||||||
| 360 ESSEX CENTER SUITE 302 | HACKENSACK | NJ | 07601 | 221487576 | 501(C)(3) | $27,500 | $0 | SITE INVESTMENT GRANT | |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | |||||||||
| ONE GUSTAVE L LEVY PLACE PO BOX | NEW YORK | NY | 10029 | 136171197 | 501(C)(3) | $363,019 | $0 | SITE INVESTMENT GRANT, IMMUNOTHERAPY | 1075 |
| INDIANA UNIVERSITY | |||||||||
| 400 E 7TH STREET POPLARS 501 | BLOOMINGTON | IN | 47405 | 356001673 | 501(C)(3) | $67,500 | $0 | FELLOW | |
| LEVINE CANCER CENTER | |||||||||
| 1021 MOREHEAD MEDICAL DRIVE | CHARLOTTE | NC | 28204 | 560529945 | 501(C)(3) | $27,500 | $0 | SITE INVESTMENT GRANT | |
| MAYO CLINIC - ROCHESTER | |||||||||
| 200 FIRST STREET SW | ROCHESTER | MN | 55905 | 416011702 | 501(C)(3) | $27,500 | $0 | SITE INVESTMENT GRANT | |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | |||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 501(C)(3) | $62,500 | $0 | SITE INVESTMENT GRANT, FELLOW, TRANSLATIONAL CORE, PREVENTION | |
| OHIO STATE UNIVERSITY RESEARCH FOUNDATION | |||||||||
| B321 STARLING LOVING HALL 320 WEST | COLUMBUS | OH | 43210 | 316401599 | 501(C)(3) | $62,500 | $0 | SITE INVESTMENT GRANT | 10TH AVENUE |
| SARAH CANNON RESEARCH INSTITUTE LLC | |||||||||
| 3322 WEST END ROAD SUITE 900 | NASHVILLE | TN | 37203 | 201557751 | $27,500 | $0 | SITE INVESTMENT GRANT | ||
| THE UNIVERSITY OF CHICAGO | |||||||||
| 5841 S MARYLAND AVENUE MC 2115 | CHICAGO | IL | 60637 | 362177139 | STATE OF ILLINOIS | $86,996 | $0 | SITE INVESTMENT GRANT, FELLOW | |
| UCSF MYELOMA RESEARCH PROGRAM | |||||||||
| 1855 FOLSOM STREET ROOM 423 | SAN FRANCISCO | CA | 94103 | 946036493 | 501(C)(3) | $65,000 | $0 | SITE INVESTMENT GRANT | |
| UNIVERSITY OF MICHIGAN | |||||||||
| 4310 CANCER CENTER 1500 EAST | ANN ARBOR | MI | 48109 | 386006309 | STATE OF MICHIGAN | $25,000 | $0 | SITE INVESTMENT GRANT | MEDICAL CENTER DRIVE |
| UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL CENTER | |||||||||
| 5323 HARRY HINES BOULEVARD | DALLAS | TX | 75390 | 756002868 | STATE OF TEXAS | $27,500 | $0 | SITE INVESTMENT GRANT | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 660 E EUCLID AVENUE | ST LOUIS | MO | 63110 | 430653611 | 501(C)(3) | $27,500 | $0 | SITE INVESTMENT GRANT, IMMUNOTHERAPY | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 18 | Total501c3OrgCnt |
| Total Other Org | 1 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | THE OVERALL RESEARCH BUDGET IS PRESENTED TO THE MMRF BOARD. THE BUDGET IS BROKEN DOWN INTO THREE MAIN CATEGORIES WHICH INCLUDE THE FOLLOWING GRANT TYPES: A) DATA BANK: MMRF-SPONSORED LONGITUDINAL MOLECULAR AND IMMUNE STUDIES (COMMPASS AND THE MMRF CURECLOUD). B) LEARNING NETWORK: GATEWAYS, DATA ANALYSIS INITIATIVES, TRANSLATIONAL SITE INVESTMENTS GRANTS (MMRF TRANSLATIONAL NETWORK), TRANSLATIONAL AND IMMUNE PROGRAM GRANTS, RESEARCH FELLOW GRANTS. C) CLINIC: CLINICAL- SITE INVESTMENT GRANTS, CLINICAL FUNDING AGREEMENT GRANTS, PRECISION MEDICINE GRANTS. THE BUDGET SPEND IS INITIALLY APPROVED BY THE PROGRAMMING COMMITTEE, AND THEN THE BOARD GIVES FINAL APPROVAL. 2. DURING THE YEAR, THERE ARE RESEARCH SPEND MEETINGS WITH THE CEO AND CFO TO DISCUSS PROGRESS ON MAKING THE AWARDS. ADDITIONALLY, ANY CHANGES OR REFORECASTS ARE REVIEWED. IF A CHANGE ARISES THAT IS GREATER THAN $1M, THEN IT IS PRESENTED TO THE AUDIT AND FINANCE COMMITTEE AS WELL AS THE PROGRAMMING COMMITTEE TO DISCUSS. 3. THERE ARE TWO DISTINCT TYPES OF GRANTS BEING AWARDED: CLASSICAL RESEARCH SUPPORT GRANTS AND CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS. CLASSICAL RESEARCH GRANTS: GRANTS ARE REVIEWED BY AN EXTERNAL GROUP OF SCIENTISTS WITH THE APPROPRIATE AREAS OF EXPERTISE. SCIENTIFIC RATINGS USE THE CURRENT NIH SCORING SYSTEM OF 1-9 WITH 1 DEMONSTRATING THE HIGHEST SCIENTIFIC MERIT AND 9 BEING THE LOWEST. EACH PROPOSAL IS EVALUATED BY TWO INDEPENDENT OUTSIDE REVIEWERS AND THE SCORES ARE AVERAGED TOGETHER. MOST GRANTS CHOSEN SCORE AT LEAST A 3 OR BETTER. ONCE THE GRANTS ARE RATED EXTERNALLY, FINAL REVIEW IS DONE BY THE MMRF RESEARCH LEADERSHIP AND RECOMMENDATIONS ARE MADE TO THE CEO AND CFO TO CONFIRM THE FINAL SELECTION. AFTER EACH GRANT TYPE AWARD IS MADE, AN AWARD LETTER IS SENT TO THE RECIPIENT AND AN EMAIL IS SENT TO THE CFO NOTIFYING THEM OF THE GRANTS AWARDED AND TO PROCEED WITH MAKING THE ACCRUAL FOR THE GRANT. AFTER THE FIRST PAYMENT THE RESEARCHER SENDS IN THE REQUIRED PROGRESS REPORT TO RECEIVE REMAINING PAYMENTS. MMRF CONDUCTS A REVIEW PROCESS, DURING WHICH THE INVESTIGATOR'S PROGRESS REPORT IS REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS THAT APPROPRIATE PROGRESS WAS MADE AND THE FINDINGS SUPPORT CONTINUES STUDY, HE/SHE PRESENTS THE PROGRESS AND FINDINGS TO AN APPROVAL COMMITTEE FOR A FUNDING RELEASE. CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS: GRANT PROPOSALS TO SUPPORT MMRF/C CLINICAL OR TRANSLATIONAL SITES ARE REVIEWED BY MMRF RESEARCH STAFF AND LEADERSHIP IN COLLABORATION WITH OUTSIDE ADVISORS. THE MMRF RESEARCH LEADERSHIP THEN MAKES RECOMMENDATIONS TO THE CEO FOR FINAL APPROVAL. AFTER EACH GRANT TYPE AWARD IS APPROVED, AN AWARD LETTER IS SENT TO THE RECIPIENT AND AN EMAIL IS SENT TO THE CFO NOTIFYING THEM OF THE GRANTS AWARDED AND TO PROCEED WITH MAKING THE ACCRUAL FOR THE GRANT. SUCH GRANTS ARE TYPICALLY RENEWED ANNUALLY OR ARE MULTI-YEAR IN NATURE. CONTINUATION/RENEWAL IS AWARDED BASED ON MILESTONES ESTABLISHED UPON INITIATION OF THE PROGRAM. A CONFLICT OF INTEREST POLICY IS IN PLACE AND A COMMITTEE REVIEWS ANY ISSUES THAT MIGHT ARISE WITH ANY GRANTS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (1) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (16 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KATHY GIUSTI | ||||||||||||||
| FOUNDER & DIRECTOR | $0 | $0 | $120,000 | $0 | $616,667 | $0 | $200 | $0 | $0 | $0 | $736,867 | $0 | $0 | $0 |
| MICHAEL ANDREINI | ||||||||||||||
| PRESIDENT & CEO | $325,049 | $0 | $135,000 | $0 | $34,021 | $0 | $15,050 | $0 | $8,358 | $0 | $517,478 | $0 | $0 | $0 |
| PETER KOSA | ||||||||||||||
| MIF MANAGING DIRECTOR | $274,116 | $0 | $115,000 | $0 | $40,542 | $0 | $12,400 | $0 | $21,197 | $0 | $463,255 | $0 | $0 | $0 |
| ROBERT MIANI | ||||||||||||||
| TREASURER & CFO | $249,179 | $0 | $91,600 | $0 | $19,088 | $0 | $16,032 | $0 | $8,764 | $0 | $384,663 | $0 | $0 | $0 |
| ANNE QUINN YOUNG | ||||||||||||||
| CHIEF MISSION OFFICER | $251,766 | $0 | $64,000 | $0 | $25,245 | $0 | $12,235 | $0 | $6,614 | $0 | $359,860 | $0 | $0 | $0 |
| KAREN DIETZ | ||||||||||||||
| SECRETARY CAO & GENERAL COUNSEL | $202,155 | $0 | $48,000 | $0 | $21,026 | $0 | $12,994 | $0 | $9,986 | $0 | $294,161 | $0 | $0 | $0 |
| GEORGE MULLIGAN | ||||||||||||||
| CHIEF SCIENTIFIC OFFICER | $222,208 | $0 | $0 | $0 | $11,352 | $0 | $9,546 | $0 | $16,270 | $0 | $259,376 | $0 | $0 | $0 |
| CHRISTOPHER WILLIAMS | ||||||||||||||
| VP OF ALLIANCE MANAGEMENT | $196,652 | $0 | $22,000 | $0 | $10,403 | $0 | $9,480 | $0 | $19,418 | $0 | $257,953 | $0 | $0 | $0 |
| MINDY FLINN | ||||||||||||||
| VP OF DEVELOPMENT | $191,010 | $0 | $22,000 | $0 | $14,143 | $0 | $9,400 | $0 | $18,193 | $0 | $254,746 | $0 | $0 | $0 |
| GREG RUBENSTEIN | ||||||||||||||
| VP OF MARKETING | $176,261 | $0 | $21,000 | $0 | $14,825 | $0 | $8,807 | $0 | $21,103 | $0 | $241,996 | $0 | $0 | $0 |
| HEARN CHO | ||||||||||||||
| CHIEF MEDICAL OFFICER | $154,682 | $0 | $38,000 | $0 | $16,151 | $0 | $8,353 | $0 | $0 | $0 | $217,186 | $0 | $0 | $0 |
| EVA M LEPISTO | ||||||||||||||
| VP OF INFORMATICS | $184,438 | $0 | $10,000 | $0 | $10,474 | $0 | $9,620 | $0 | $986 | $0 | $215,518 | $0 | $0 | $0 |
| CHARLES VOLPE | ||||||||||||||
| DIRECTOR, PR & COMMUNCIATIONS | $148,543 | $0 | $14,000 | $0 | $11,378 | $0 | $0 | $0 | $22,134 | $0 | $196,055 | $0 | $0 | $0 |
| JOANNE PUGLIA | ||||||||||||||
| SR DIRECTOR FINANCE, CONTROLLER | $151,600 | $0 | $17,600 | $0 | $16,660 | $0 | $7,437 | $0 | $2,699 | $0 | $195,996 | $0 | $0 | $0 |
| TODD BROOKS | ||||||||||||||
| SR DIRECTOR, DEVELOPMENT | $155,996 | $0 | $13,000 | $0 | $10,547 | $0 | $7,176 | $0 | $820 | $0 | $187,539 | $0 | $0 | $0 |
| HEATHER STEIGER | ||||||||||||||
| DIRECTOR, DIGITAL MARKETING | $147,199 | $0 | $13,000 | $0 | $9,492 | $0 | $0 | $0 | $16,330 | $0 | $186,021 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 4A | KATHY GIUSTI, FOUNDER AND FORMER CHIEF MISSION OFFICER, RECEIVED A $250,000 SEVERANCE PAYMENT IN HER 2022 W-2. |
| PART I, LINE 7 | INDIVIDUALS INCLUDED IN SCHEDULE J, PART II RECEIVED A DISCRETIONARY BONUS DURING CALENDAR YEAR 2022, WHICH WAS INCLUDED IN COLUMN B(II) HEREIN AND IN THEIR 2022 FORM W-2, BOX 5, AS TAXABLE MEDICARE WAGES. |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 24 | ContributionCnt |
| Noncash Contributions Rpt F990 | $191,034 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | AVG. SELLING PRICE | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form8283 Received | 0 | Form8283ReceivedCnt |
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B): | FormAndLineReferenceDesc |
| Explanation | THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (12 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART I, LINE 1: | MMRF ACCOMPLISHMENTS FOR 2022: THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AND ITS WHOLLY OWNED SUBSIDIARIES, THE MULTIPLE MYELOMA RESEARCH CONSORTIUM, LLC ("MMRC") AND MYELOMA INVESTMENT FUND, LLC ("MIF"), COLLECTIVELY REFERRED TO AS "THE MMRF,". IN 2022, WE CONTINUED TO ADVANCE THE KEY INITIATIVES OF OUR STRATEGIC PLAN WHICH IS ANCHORED BY THREE STRATEGIC OBJECTIVES, WITH A CENTRALIZED FOCUS ON DEI AND HEALTH EQUITY. - ACCELERATE THE DEVELOPMENT OF NOVEL THERAPIES - DRIVE OPTIMAL AND MORE PERSONALIZED TREATMENT APPROACHES - EMPOWER PATIENTS AND THE MYELOMA COMMUNITY PATIENT SERVICES AND EDUCATION THE MMRF PROVIDES PATIENTS, CAREGIVERS, AND HEALTHCARE PROVIDERS WITH THE RESOURCES THEY NEED TO MAKE INFORMED TREATMENT DECISIONS AND TO OPTIMIZE THEIR CARE. THESE INCLUDE ON-DEMAND INFORMATION AND RESOURCES ON TREATMENT OPTIONS, AND CLINICAL TRIALS TAILORED TO MEET PATIENTS EXACTLY WHERE THEY ARE ON THEIR JOURNEY. OUR PROGRAMS INCLUDE WEBINARS, PATIENT SUMMITS, BROCHURES, AND CONTINUING MEDICAL EDUCATION-ACCREDITED PROGRAMS FOR HEALTHCARE PROFESSIONALS. IN ADDITION, OUR PATIENT NAVIGATION CENTER ENABLES MYELOMA PATIENTS AND CAREGIVERS TO CONNECT WITH PATIENT NAVIGATORS FOR SUPPORT. PATIENTS CAN CONNECT WITH A PATIENT NAVIGATOR VIA PHONE, EMAIL, OR ONLINE WEB FORM. - PATIENT EDUCATION WEBINARS AND SUMMITS REACHED 16,400 PATIENTS AND CAREGIVERS IN 2022. - IN 2022, THE MMRF PATIENT NAVIGATION CENTER ANSWERED 4,200 CALLS AND ADDRESSED 3,200 CASES. ITS EXEMPLARY SERVICE HAS EARNED A 5-STAR SATISFACTION RATING FROM THE MYELOMA COMMUNITY. |
| FORM 990, PART III, LINE 1: | THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) IS THE LARGEST NONPROFIT IN THE WORLD SOLELY FOCUSED ON ACCELERATING ACUREFOR EACH AND EVERY MULTIPLE MYELOMA PATIENT. WE DRIVE THE DEVELOPMENT AND DELIVERY OF NEXT-GENERATION THERAPIES, LEVERAGE DATA TO IDENTIFY OPTIMAL AND MORE PERSONALIZED TREATMENT APPROACHES, AND EMPOWER MYELOMA PATIENTS AND THE BROADER COMMUNITY WITH INFORMATION AND RESOURCES TO EXTEND THEIR LIVES. CENTRAL TO OUR MISSION IS OUR COMMITMENT TO ADVANCING HEALTH EQUITY SO THAT ALL MYELOMA PATIENTS CAN BENEFIT FROM THE SCIENTIFIC AND CLINICAL ADVANCES WE PURSUE. SINCE OUR INCEPTION, THE MMRF HAS RAISED OVER $500 MILLION FOR RESEARCH, OPENED NEARLY 100 CLINICAL TRIALS, AND HELPED BRING 15+ FDA-APPROVED THERAPIES TO MARKET, WHICH HAVE TRIPLED THE LIFE EXPECTANCY OF MYELOMA PATIENTS. |
| FORM 990, PART VI, SECTION A, LINE 2 | KATHY GIUSTI, FOUNDER & FORMER CHIEF MISSION OFFICER, AND KAREN ANDREWS, BOARD MEMBER HAVE A FAMILY RELATIONSHIP. |
| FORM 990, PART VI, SECTION A, LINE 4 | SIGNIFICANT CHANGES WERE MADE TO THE BYLAWS IN MAY 2022, WHICH INCLUDED: - DISSOLVING THE CONFLICT OF INTEREST COMMITTEE AND REALLOCATING RESPONSIBILITIES TO THE BOARD DEVELOPMENT COMMITTEE FOR ANNUAL REVIEW OF BOARD AND MANAGEMENT DISCLOSURES AND REALLOCATING RESPONSIBILITIES TO THE AUDIT AND FINANCE COMMITTEE FOR MONETARY RELATED CONFLICTS - RENAMING THE BOARD DEVELOPMENT COMMITTEE TO THE BOARD GOVERNANCE COMMITTEE TO BETTER REFLECT ROLE IN OVERALL GOVERNANCE, NOT JUST DEVELOPMENT AND INCLUDE EXPLICIT RESPONSIBILITIES FOR REVIEWING AND UPDATING BYLAWS, CODE OF ETHICS, CORPORATE RESPONSIBILITIES AND DEIB POLICIES - REELECTING A TWO YEAR TERM FOR THE BOARD CHAIR AND BOARD VICE CHAIR AND UPON EXPIRATION OF THE TWO YEAR TERM THE BOARD CHAIR, VICE CHAIR OR ANOTHER COMMITTEE CHAIR MAY ASSUME THE ROLE OF BOARD CHAIR AND A VICE CHAIR WOULD BE ELECTED BY THE BOARD OF DIRECTORS. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 IS FIRST REVIEWED WITH THE CEO OF THE FOUNDATION. ONCE REVIEWED WITH THE CEO, THE FORM 990 IS EMAILED TO EACH BOARD MEMBER. EACH BOARD MEMBER REVIEWS THE FORM 990 AND IF ANY QUESTIONS ARISE, THEY ARE COMMUNICATED TO THE FOUNDATION AND ADDRESSED. AFTER ALL QUESTIONS ARE ADDRESSED, THE FORM 990 IS SUBMITTED TO THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C | THE ORGANIZATION'S CONFLICT OF INTEREST POLICY APPLIES TO ANY DIRECTOR, OFFICER, OR MEMBER OF A STANDING OR ADVISORY COMMITTEE WITH POWERS DELEGATED BY THE MMRF BOARD OF DIRECTORS WHO MAY HAVE A DIRECT OR INDIRECT FINANCIAL INTEREST (I.E. "INTERESTED PERSON"). DUTY TO DISCLOSE A POTENTIAL CONFLICT OF INTEREST: ANY INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OR AUDIT COMMITTEE AND MUST BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE BOARD, MEMBERS OF THE AUDIT COMMITTEE AND ALL MEMBERS OF ANY COMMITTEE CONSIDERING THE PROPOSED CONTRACT OR TRANSACTION. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR AUDIT COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR AUDIT COMMITTEE MEMBERS, AS APPLICABLE, SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: I. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OR AUDIT COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE OR SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE CONTRACT OR TRANSACTION THAT RESULT IN THE CONFLICT OF INTEREST. II. THE CHAIR OF THE BOARD OR CHAIRPERSON OF THE AUDIT COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR APPOINT OR ESTABLISH AN ADVISORY COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED CONTRACT OR TRANSACTION. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR THE AUDIT COMMITTEE SHALL TAKE ALL REASONABLE STEPS TO DETERMINE WHETHER THE MMRF CAN OBTAIN A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR AUDIT COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE, BUT NOT LESS THAN TWO, OF THE DISINTERESTED DIRECTORS OR MEMBERS THEREOF WHETHER THE CONTRACT OR TRANSACTION IS IN THE MMRF'S BEST INTEREST AND IS FAIR AND REASONABLE TO THE MMRF; PROVIDED, HOWEVER, IF SUCH CONTRACT OR TRANSACTION IS APPROVED BY DISINTERESTED DIRECTORS WHO DO NOT SATISFY A QUORUM OR VOTING REQUIREMENT APPLICABLE TO THE AUTHORIZATION OF THE ACTION BY REASON OF THE MMRF'S CERTIFICATE OF INCORPORATION, BYLAWS OR A PROVISION OF LAW, THE ACTION MUST BE INDEPENDENTLY APPROVED BY SUCH INTERESTED AND DISINTERESTED DIRECTORS AS SATISFY THE APPLICABLE QUORUM OR VOTING REQUIREMENT. VIOLATION OF THE CONFLICTS OF INTEREST POLICY: III. IF THE BOARD OR AUDIT COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A DIRECTOR, OFFICER OR COMMITTEE MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM SUCH PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE OF THE DIRECTOR, OFFICER OR COMMITTEE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR AUDIT COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, THE BOARD OR AUDIT COMMITTEE, AS APPLICABLE, SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. |
| FORM 990, PART VI, SECTION B, LINE 15 | ALL SENIOR POSITIONS AND THEIR COMPENSATION ARE REVIEWED AND APPROVED BY THE HR COMMITTEE OF THE BOARD OF DIRECTORS. COMPENSATION IS BENCHMARKED AGAINST OTHER 501(C)(3)'S, RESEARCH ORGANIZATIONS, THIRD PARTY COMPENSATION DATABASE AND THEN REVIEWED BY THE COMPENSATION COMMITTEE. THE COMPENSATION APPROVAL IS DOCUMENTED IN THE MINUTES BY THE COMMITTEE. THIS PROCESS WAS LAST UNDERTAKEN IN 2022. |
| FORM 990, PART VI, SECTION C, LINE 19 | FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, FORM 990 AND FORM 1023 ARE MADE AVAILABLE FOR PUBLIC VIEWING UPON WRITTEN REQUEST AT MMRF'S HEADQUARTERS. FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE ALSO AVAILABLE AT THE ORGANIZATION'S WEBSITE: WWW.THEMMRF.ORG THE FORM 990 IS ALSO AVAILABLE ON WWW.GUIDESTAR.ORG, WWW.CHARITYNAVIGATOR.ORG, AND OTHER SIMILAR WEBSITES. |
| FORM 990, PART VII, SECTION A, LINE 1: | KATHY GIUSTI, FOUNDER AND FORMER CHIEF MISSION OFFICER, WAS NOT COMPENSATED IN THE CAPACITY OF A BOARD MEMBER, BUT IN THE CAPACITY OF A BRAND AMBASSADOR SERVICES CONSULTANT DURING 2022. |
| FORM 990, PART IX, LINE 11G | CONSULTING: PROGRAM SERVICE EXPENSES 3,897,213. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 545,913. TOTAL EXPENSES 4,443,126. MEDICAL PROFESSIONALS: PROGRAM SERVICE EXPENSES 3,026,328. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 423,922. TOTAL EXPENSES 3,450,250. RECRUITING COSTS & TEMPORARY HELP: PROGRAM SERVICE EXPENSES 269,446. MANAGEMENT AND GENERAL EXPENSES 34,487. FUNDRAISING EXPENSES 73,556. TOTAL EXPENSES 377,489. |
| FORM 990, PART XI, LINE 9: | GRANT REFUND 230,250. |
| FORM 990, PART XII, LINE 2C: | THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AUDIT/FINANCE COMMITTEE RECOMMENDS THE AUDITOR TO THE BOARD, AND THE BOARD APPOINTS THE AUDITOR. THE BOARD ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS. THE POLICY FOR SELECTION AND OVERSIGHT OF THE INDEPENDENT AUDITORS HAS NOT CHANGED SINCE LAST YEAR. |
Schedule R IRS990ScheduleR
Id Disregarded Entities IdDisregardedEntitiesGrp (2 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Total IncomeTotalIncomeAmt | End Of Year AssetsEndOfYearAssetsAmt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt |
|---|---|---|---|---|---|---|---|---|---|
| MYELOMA INVESTMENT FUND LLC | |||||||||
| 383 MAIN AVENUE 5TH FLOOR | NORWALK | CT | 06851 | 471162865 | VENTURE PHILANTHROPY FUND | DE | $2,627,469 | $19,892,015 | THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC |
| MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC | |||||||||
| 383 MAIN AVENUE 5TH FLOOR | NORWALK | CT | 06851 | 471142650 | FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCH | CT | $6,154,809 | $2,589,106 | THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC |